Halozyme expects $1.86B-$1.925B 2026 revenue while raising non-GAAP EPS to $8.75-$9.05
Earnings Call Insights: Halozyme Therapeutics (HALO) Q3 2026
Management view
"I'm pleased to report another exceptionally strong quarter for Halozyme as more patients, physicians and health care systems experience the benefits of subcutaneous delivery with ENHANZE." (President, CEO & Director Helen Torley)
Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.